Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €112.02 EUR
Change Today +0.418 / 0.37%
Volume 1.0K
As of 10:47 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

vertex pharmaceuticals inc (VX1) Snapshot

Open
€111.46
Previous Close
€111.60
Day High
€113.00
Day Low
€111.19
52 Week High
03/20/15 - €126.28
52 Week Low
08/8/14 - €62.60
Market Cap
27.3B
Average Volume 10 Days
359.0
EPS TTM
--
Shares Outstanding
243.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERTEX PHARMACEUTICALS INC (VX1)

vertex pharmaceuticals inc (VX1) Related Businessweek News

View More BusinessWeek News

vertex pharmaceuticals inc (VX1) Details

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. It markets KALYDECO (ivacaftor) to treat patients of six years of age and older with CF who have the mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene in the United States, Australia, Canada, and the European Union. The company also provides INCIVEK for the treatment of adults with genotype 1 hepatitis C virus infection. In addition, it is developing CFTR correctors, including lumacaftor in combination with ivacaftor, which has completed Phase III development program; and VX-661 in combination with ivacaftor, which is in Phase III development program. Further, it identifies and develops next-generation CFTR corrector compounds; and is involved in the research and early-stage development programs, including programs in the areas of oncology and neurology. Vertex Pharmaceuticals Incorporated sells its products principally to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers in international markets. The company has collaboration agreements with Cystic Fibrosis Foundation Therapeutics Incorporated; BioAxone Biosciences, Inc.; and Janssen Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

1,830 Employees
Last Reported Date: 02/13/15
Founded in 1989

vertex pharmaceuticals inc (VX1) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $789.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $600.0K
Special Counsel to the Chief Executive Office...
Total Annual Compensation: $465.0K
Compensation as of Fiscal Year 2014.

vertex pharmaceuticals inc (VX1) Key Developments

Vertex Pharmaceuticals Incorporated - Special Call

To provide more information on the approval of ORKAMBI

Vertex Pharmaceuticals Incorporated Announces U.S. Food and Drug Administration Approval of ORKAMBI (lumacaftor/ivacaftor)

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) approved ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people ages 12 and older with two copies of the F508del mutation. It is only indicated for these patients, who can be identified with a genetic test. Cystic fibrosis is a rare, life-threatening genetic disease. People with two copies of the F508del mutation represent the large group of people with CF. Of the 30,000 people in the United States with CF, approximately 8,500 ages 12 and older have two copies of the F508del mutation. ORKAMBI will be available for shipment to specialty pharmacies in the United States within days. The approval of ORKAMBI was based on data from two Phase 3 studies (TRAFFIC and TRANSPORT) that enrolled more than 1,100 people with CF ages 12 and older with two copies of the F508del mutation. Patients treated with ORKAMBI experienced statistically significant improvements in lung function. Patients also experienced reductions in pulmonary exacerbations and improvements in body mass index (BMI). The most common adverse events included shortness of breath and/or chest tightness, upper respiratory tract infection (common cold) and gastrointestinal symptoms (including nausea, diarrhea, or gas).

Vertex Pharmaceuticals Incorporated Appoints Sangeeta N. Bhatia as an Independent Director

Vertex Pharmaceuticals Incorporated announced that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018. Dr. Bhatia is a physician and engineer and has been a professor at the Massachusetts Institute of Technology (MIT) since 2005. She currently serves as the John J. and Dorothy Wilson Professor of Health Sciences at the MIT Institute for Medical Engineering and Science and Electrical Engineering and Computer Science (EECS). She also currently serves as a Biomedical Engineer in the Department of Medicine for Brigham and Women's Hospital, an investigator for the Howard Hughes Medical Institute, a member of the Koch Institute for Integrative Cancer Research at MIT and a member of the Broad Institute.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VX1:GR €112.02 EUR +0.418

VX1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $68.21 USD +1.30
BioMarin Pharmaceutical Inc $144.60 USD +0.28
Incyte Corp $104.17 USD -0.20
Jazz Pharmaceuticals PLC $188.67 USD +3.63
Sigma-Aldrich Corp $139.55 USD +0.12
View Industry Companies
 

Industry Analysis

VX1

Industry Average

Valuation VX1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 50.1x
Price/Book 31.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.